Clinical trial
Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms…
NCT00331045 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry · Terminated
Key facts
| NCT number | NCT00331045 |
|---|---|
| Title | Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid |
| Official title | Clinical Evaluation of Alvimopan (SB767905) on Constipation and Related Symptoms Associated With Opioid -A Placebo-controlled Double-blind Study in Cancer Patients- |
| Lead sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Constipation |
| Intervention type | Drug |
| Interventions | alvimopan, Placebo, Alvimopan 0.5 mg/day, Alvimopan 1 mg/day |
| Enrollment | 21 |
| Start date | Apr 1, 2006 |
| Primary completion | Oct 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | May 29, 2006 |
| Last update posted | Sep 2, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: